[{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Peking University","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Peking University \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Peking University \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Lund University Hospital","sponsor":"Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Lund University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lund University Hospital \/ Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group","highestDevelopmentStatusID":"10","companyTruncated":"Lund University Hospital \/ Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group"}]

Find Clinical Drug Pipeline Developments & Deals for Epirubicin Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.

                          Product Name : Tuznue

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 31, 2024

                          Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peking University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Peking University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 22, 2022

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.

                          Product Name : Tuznue

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 14, 2022

                          Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Lund University Hospital

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Lund University Hospital

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 06, 2020

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Henan Cancer Hospital

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Henan Cancer Hospital

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 27, 2018

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Jiangsu Hengrui Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Fudan University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Fudan University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 16, 2015

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Shanghai Zhongshan Hospital | Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          West German Study Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          West German Study Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 15, 2014

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : AGO Germany

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OHSU Knight Cancer Institute

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          OHSU Knight Cancer Institute

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2014

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Bayer AG | Oregon Health and Science University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Australasian Gastro-Intestinal Trials Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Australasian Gastro-Intestinal Trials Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Study Phase : Phase II/ Phase III

                          Sponsor : National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 19, 2013

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          West German Study Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          West German Study Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 30, 2013

                          Lead Product(s) : Epirubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank